The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

Documenti analoghi

• Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
  di: Oscier, David, et al.
  Pubblicazione: (2010)
• The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial
  di: Oscier, David, et al.
  Pubblicazione: (2016)
• The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
  di: Else, Monica, et al.
  Pubblicazione: (2015)
• The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial
  di: Else, Monica, et al.
  Pubblicazione: (2021)
• Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial
  di: Strefford, JC, et al.
  Pubblicazione: (2015)